The GSK name and elements of the incumbent orange logo have been retained in the new identity. Stevens says that the decision to retain the orange was partly driven by the fact that “the world of ...

This report presents key facts and figures about the British pharmaceutical company GSK, formerly known as GlaxoSmithKline. GSK is one of the world's 10 largest pharmaceutical companies.

GSK), and Teva Pharmaceutical (NYSE:TEVA), for violating patent listing procedures in the FDA's official register of drugs called "Orange Book." Drugmakers can avoid rival products, including ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £16.50. The company’s shares closed last ...

(Bloomberg) -- GSK Plc and Flagship Pioneering Inc. entered a partnership to develop as many as 10 new drugs in a deal that ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

GSK’s vaccine portfolio. GSK’s portfolio of more than 20 marketed vaccines, one of the industry’s broadest, protects people against diseases such as meningitis, shingles, polio, measles ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50. The company’s shares opened today at p1,644. ...

GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza mRNA Vaccine GSK announced positive phase 2 trial results for its mRNA seasonal flu vaccine, showing strong immune. Vandana ...

GSK Cars: Your Premier Destination for Quality Vehicles At GSK Cars, we pride ourselves on offering an extensive selection of high-quality vehicles to suit every need and budget. Located conveniently ...

GSK Plc’s experimental vaccine for herpes failed in an early-stage trial, halting an effort to bring the first shot for the condition to market. While there were no safety concerns, the trial ...